Introduction {#section1-S1013702519500124}
============

Osteoarthritis (OA) is a progressive degenerative articular disease characterized by marginal osteophyte formation, destruction of joint cartilage, and subchondral bone changes.^[@bibr1-S1013702519500124],[@bibr2-S1013702519500124]^ Clinical symptomology includes joint pain, loss of joint functions, and limitation of joint range of motions.^[@bibr3-S1013702519500124]^ OA mostly affects weight-bearing joints such as knee and hip. The disease rate increases with increase in age and obesity, with arthritis pains and dysfunction affecting patient's quality of life (QoL).^[@bibr4-S1013702519500124]^ OA is one of the commonest causes of disability among elderly individuals.^[@bibr5-S1013702519500124]^ It has been shown that 50% of people over the age of 65 years have radiological features of OA, with roughly 10% of men and 18% of women suffering symptomatic OA.^[@bibr6-S1013702519500124]^

The aims of knee OA treatment are to reduce pain and improve function or quality of life based on interferential current (IFC) approach.^[@bibr7-S1013702519500124]^ Moreover, drug treatments for the elderly are often limited, producing suboptimal benefits because of comorbidities, polypharmacy, and the associated high risk of side effects of drugs.^[@bibr7-S1013702519500124],[@bibr8-S1013702519500124]^ No pharmacological treatments are recommended for the treatment of OA, such as exercises and physical therapy modalities to treat patients with knee OA, in an attempt to limit the side effects of medication. In addition to the use of heat and cold, therapeutic ultrasound (US) and interferential current were also used.^[@bibr9-S1013702519500124]^

IFC approach is characterized by superimposing of two slightly different medium-frequency currents (4,000 Hz) to form a new medium-frequency current with an amplitude modulation at low frequency (0--250 Hz).^[@bibr10-S1013702519500124],[@bibr11-S1013702519500124]^ It has been stated that amplitude-modulated frequency (AMF) is the main electro-analgesic component of IFC.^[@bibr12-S1013702519500124]^ IFC therapy achieves its pain modulation by stimulating afferent large-diameter fibers. Studies have reported IFC therapy's effectiveness in the treatment of painful musculoskeletal problems such as sports injuries; bruising and swelling, low back pain, osteoarthritis, rheumatoid arthritis, and muscular pain.^[@bibr13-S1013702519500124]-[@bibr15-S1013702519500124]^

Therapeutic US is one of the most frequently applied electrotherapeutic modalities in orthopedics physiotherapy.^[@bibr16-S1013702519500124]^ It produces thermal effects which increase tissue metabolism, collagen elasticity, and capillary blood flow and reduce skeletal muscle spasm.^[@bibr17-S1013702519500124]^ Therapeutic ultrasound is often used in the management of knee osteoarthritis and it is believed to be effective in enhancing inflammatory response, tissue repair, and is absorbed especially in tissues with high collagen contents.^[@bibr18-S1013702519500124]^ Besides the individual therapeutic effects of ultrasound and interferential current therapies, their combination \[i.e., combination therapy (CT)\] is more effective than each of them applied separately in eliciting localized analgesia on previously detected painful areas.^[@bibr19-S1013702519500124]^

Infrared radiation with wavelength range from 750 nm to 1 mm can stimulate the production of nitric oxide (NO), enhancing inflammatory response, tissue repair, and is absorbed especially in tissues with high collagen contents.^[@bibr29-S1013702519500124],[@bibr34-S1013702519500124]^ Clinical investigations of the efficacy of OA therapies should include symptoms (such as pain), function, disability, and health-related quality of life (HRQoL).^[@bibr8-S1013702519500124],[@bibr20-S1013702519500124]^ Further intensive research focusing on the therapeutic effects of ultrasound, interferential current, and infrared on patients with knee OA is required.^[@bibr7-S1013702519500124],[@bibr20-S1013702519500124],[@bibr21-S1013702519500124]^ To our knowledge, there have been no reports to date that evaluated the effects of combination therapy and infrared on pain, functional activity, and HRQoL of elderly patients with knee OA. We hypothesized there would be significant difference in the administrations of combination therapy and infrared radiation to improve HRQoL, relieve pain, and improve functional activities in patients with knee osteoarthritis. This study, therefore, is aimed at investigating the differences between the combined application of therapeutic ultrasound and interferential current therapies (combination therapy) and infrared lamp on pain, functional activities, and HRQoL of elderly patients with knee osteoarthritis.

Methods {#section2-S1013702519500124}
=======

Participants {#section2.1-S1013702519500124}
------------

Sixty outpatients with knee OA, diagnosed according to the American College of Rheumatology criteria, were recruited.^[@bibr22-S1013702519500124]^ Patients were excluded from the study if they had any knee diseases other than OA. Patients with serious concomitant systemic diseases, patients who had corticosteroid or hyaluronic acid injection in the last one month, and patients with previous history of any electrotherapy contraindications were excluded from the study. Subsequently, patients were made to understand the research protocols, before they were randomly allocated into two groups \[combination therapy group (CTG) and infrared radiation group (IRG)\].

Design {#section2.2-S1013702519500124}
------

A prospective randomized controlled clinical trial was used.

### Randomization {#section2.2.1-S1013702519500124}

Patients were allocated to either CTG or IRG. The principle of block randomization was used to assign the patients to the groups, with a block size of four. Participants were allocated to their groups by sealed envelope containing their group assignment, which they opened when they were recruited into the study. One physiotherapist enrolled all the participants, and the other physiotherapist generated the allocation sequence and assigned participants to their groups as shown in the flowchart in [Fig. 1](#figureF1-S1013702519500124){ref-type="fig"}.

![Consort flowchart depicting the participants from enrolment to analysis.](hkpj-39-133-g001){#figureF1-S1013702519500124}

Measurement {#section2.3-S1013702519500124}
-----------

### Pain {#section2.3.1-S1013702519500124}

Pain intensity was assessed on full weight bearing using the visual analog scale (VAS). Participants were asked to indicate the level of their pain between 0 (no pain) and 10 (severe pain), and were instructed not to under- or over-estimate it. The VAS is a single-item numerical scale normally in a straight horizontal or vertical line of fixed length, usually 10 cm (i.e., 100 mm).^[@bibr23-S1013702519500124]^ The ends are defined as the extreme limits of the parameter to be measured with anchor points 0 (no pain) and 10 (maximum pain). It is a highly reliable instrument for measuring pain,^[@bibr24-S1013702519500124]^ with high psychometric values.^[@bibr25-S1013702519500124]-[@bibr28-S1013702519500124]^

### Functional ability {#section2.3.2-S1013702519500124}

The Western Ontario and McMaster University Osteoarthritis Index (WOMAC) was used to evaluate the functional ability of the participants, at the baseline and after 12 weeks of treatments. The instrument is an OA-specific outcome measure and self-administered questionnaire with three domains consisting of 24 items. The Likert-scale version of WOMAC was used for the purpose of this study. This scale allows patients to indicate their responses on a five-point scale $\left( 0 = \text{none} \right.$, $1 = \text{mild}$, $2 = \text{moderate}$, $3 = \text{severe}$, and $\left. 4 = \text{extreme} \right)$. The higher the response indicated, the lower the level of perceived health and physical function. Studies have shown high psychometric value for the WOMAC questionnaire. The instrument has been shown to be reliable, valid, and sensitive to changes in clinical symptoms of individuals with knee and hip OA.^[@bibr29-S1013702519500124],[@bibr30-S1013702519500124]^

### HRQoL {#section2.3.3-S1013702519500124}

Participants' health-related quality of life was assessed and recorded using the 36-item Short Form Health Survey (SF-36) questionnaire at baseline and post-treatment. This is a generic HRQoL measurement tool, self-administered, and user-friendly which has been reported as valid and reliable with high internal and external consistencies.^[@bibr31-S1013702519500124]^

Procedures {#section2.4-S1013702519500124}
----------

The study was conducted at the Outpatient Units of Physiotherapy Departments of Rasheed Shekoni Specialist Hospital, Dutse, Nigeria, and the Federal Medical Centre Birnin Kudu, Jigawa State, Nigeria. The study was approved by the Biomedical Research and Ethics Committee (BREC) of the University of KwaZulu-Natal, Durban, South Africa, and the Ethical Research Committee of the Ministry of Health, Jigawa State, Nigeria. Patients were briefed on the study protocol and signed informed consent to participate in the study which commenced on 1 June 2015 and ended on 31 May 2016.

Participants' height and weight were measured and recorded. Body mass index (BMI) was calculated by dividing weight (kg) by height (m) and recorded. All assessments were conducted at baseline and at the end of 12 weeks of treatment. The primary outcome measures used to assess patients' response to the treatment were WOMAC, SF-36 questionnaire, and the VAS.

Intervention {#section3-S1013702519500124}
============

The CTG {#section3.1-S1013702519500124}
-------

Participants in the combination group underwent electro-diagnosis of the most painful knee area with continuous US (1 MHz; 0.5 W/cm^2^) and the IFC ($\text{AMF} = 100$ Hz) at tactile threshold intensity. Treatments were conducted at the intensity of continuous US (1 MHz; 1.5 W/cm^2^) applied with 5-cm transducer for 10 min using Sonoplus 920 (Sonicator Plus 920${}^{\text{®}}$; Mettler Electronics, CA, USA). Participants were comfortably positioned in supine lying with pillow supported under the treated knee. Ultrasound Transmission Gel (Aqueous gel${}^{\text{®}}$) was used as the contact medium. Two adhesive electrodes ($6 \times 6$ cm^2^) were placed opposite to each other (medial and lateral) for deeper penetrations. The US was first turned on, followed by turning of the IFC parameters as mentioned above. Participants were informed that they would experience tingling sensations which should not be unpleasant. Treatments were administered for 10 min three times a week for 12 weeks.

The IRG {#section3.2-S1013702519500124}
-------

Participants in this group were treated with luminous infrared lamp (IRR, Infraphil${}^{\text{®}}$ 150 W; Philips Electronics, Amsterdam, the Netherlands). The source of the radiation was placed at 60 cm from the patient's skin for 15 min of a treatment session and the patient was treated three times a week for 12 weeks. Participants were positioned comfortably with knee flexed 20--30^∘^ supported with a pillow. Participants were warned that they were expected to feel comfortable "mild warmth" as too much heat could lead to skin burns.

All participants received quadriceps isometric exercises of both knees for 10 min, and were asked to refrain from taking non-steroidal anti-inflammatory drug (NSAIDS) and anti-depressants throughout the study period. However, they also were advised to take acetaminophen in case of unbearable pain and other comorbid medications throughout the study period.

Statistical Analyses {#section4-S1013702519500124}
====================

Statistical analyses were conducted with version 21.0 of Statistical Package for the Social Sciences (SPSS Inc., Chicago, IL, USA). The effect size for the sample size calculation was obtained from the previous studies conducted on knee osteoarthritis.^[@bibr20-S1013702519500124],[@bibr32-S1013702519500124]^ Based on the data from these studies, it was estimated that a sample size of 30 patients in each study group would achieve a power of 80% to detect an effect size of 0.8 in the outcome measures of interest, assuming a type-I error of 0.05. Preliminary analysis was performed to check for normality, linearity, and homogeneity of variance, covariance, and multicollinearity with no serious violations noted with MAHAL. Descriptive statistics of mean, percentage, and standard deviation were used to describe the data. A one-way between-groups multivariate analysis of variance (MANOVA) was performed to investigate the differences between the combination therapy group and infrared group, four dependent variables were used for pain and physical function, and 10 dependent variables for quality of life. A $p$-value equal to or less than 0.05 was considered as statistically significant. Furthermore, standardized effect sizes (Cohen's $d$) with 95% confidence interval (CI) were included.

Results {#section5-S1013702519500124}
=======

A total of 63 patients with knee osteoarthritis participated in the study, and were randomized into CTG and IRG. During the study, three patients (one from CTG and two from IRG group) failed to follow up and were not included in the analyses ([Fig. 1](#figureF1-S1013702519500124){ref-type="fig"}). Of the 60 participants who completed the study, 42 (70%) were female and 18 (30%) were male, with a mean age of $66.3 \pm 8.91$ years. [Table 1](#table1-S1013702519500124){ref-type="table"} shows participants' demographic characteristics at the baseline. There was no statistically significant difference in gender, age, and BMI between CTG and IRG at the baseline $\left( p > 0.05 \right)$.

###### 

Patients' demographic features between CTG and IRG.

![](hkpj-39-133-t001)

                        CTG                 IRG                
  --------------------- ------------------- ------------------ ----------
  Age (years)           65.8 $\pm$ 9.21     66.8 $\pm$ 8.61    0.153
  Weight (kg)           69.29 $\pm$ 10.88   70.04 $\pm$ 9.66   0.985
  Height (m)            1.66 $\pm$ 0.08     1.67 $\pm$ 0.76    0.780
  BMI (kg/m^2^)         25.43 $\pm$ 3.8     25.54 $\pm$ 3.20   0.621
  Gender M/F, $n$ (%)   20%/80%             40%/60%            0.146^b^
  Gender ratio          4:1                 1.5:1              0.145

*Note*: BMI: Body mass index; M: male; F: female; M: Mean; SD: standard deviation. ${}^{\text{a}}p > 0.05$; ND: No data; and ${}^{\text{b}}X = 3.842$, $p = 0.146$.

Pain and functional activity scores {#section5.1-S1013702519500124}
-----------------------------------

At baseline, there was no statistically significant difference between the two groups in terms of pain and functional activities: $F = 0.208$; $p = 0.933$; Wilk's $\text{lambda} = 0.208$; and partial eta-$\text{squared} = 0.015$. The $p$-value for each dependent variable for the pain and functional activity scores is shown in [Table 2](#table2-S1013702519500124){ref-type="table"}.

###### 

Baseline comparison of VAS and WOMAC scores between CTG and IRG.

![](hkpj-39-133-t002)

                 CTG                IRG                                 
  -------------- ------------------ ------------------- ------- ------- -------
  VAS            7.07 $\pm$ 1.74    6.24 $\pm$ 3.12     0.692   0.612   0.409
  [WOMAC]{.ul}                                                          
  Pain           18.77 $\pm$ 2.78   20.17 $\pm$ 13.38   0.02    0.001   0.960
  Stiffness      5.77 $\pm$ 1.00    5.13 $\pm$ 2.06     0.645   0.001   0.832
  PF             56.10 $\pm$ 7.35   14.83 $\pm$ 16.22   0.086   0.001   0.770

*Note*: WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; M: mean; SD: standard deviation; "\*" denotes the significance level, $p < 0.05$. The $p$-values are for parametric test and independent sample $t$-test for comparison groups.

There was a statistically significant difference between the two groups in terms of pain and functional activities after 12 weeks of intervention: $F = 772.64$; $p = 0.000$; Wilk's $\text{lambda} = 772.64$; and partial eta-$\text{squared} = 0.983$. When the results for the dependent variables were considered separately, using a Bonferroni-adjusted alpha level of 0.012, all the variables were statistically significant as shown in [Table 3](#table3-S1013702519500124){ref-type="table"}.

###### 

Post-treatment changes between CTG and IRG following 12 weeks of treatment.

![](hkpj-39-133-t003)

                     CTG                IRG                                  
  ------------------ ------------------ ------------------- -------- ------- ---------
  VAS                2.23 $\pm$ 4.34    6.24 $\pm$ 3.12     43.6     0.983   0.000\*
  [WOMAC (%)]{.ul}                                                           
  Pain               16.97 $\pm$ 3.38   20.17 $\pm$ 13.38   246.08   0.809   0.000\*
  Stiffness          7.13 $\pm$ 2.06    10.33 $\pm$ 0.80    7.66     0.116   0.008\*
  PF                 45.79 $\pm$ 9.08   14.83 $\pm$ 16.22   266.99   0.973   0.000\*

*Note*: WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; M: mean; SD: standard deviation; "\*" denotes the significance level, $p < 0.012$.

HRQoL {#section5.2-S1013702519500124}
-----

At baseline, there was no statistically significant difference between the two groups in terms of quality of life using SF-36: $F = 1.56$; $p = 0.143$; Wilk's $\text{lambda} = 0.73$; and partial eta-$\text{squared} = 0.263$. The $p$-value for each dependent variable for the quality of life is shown in [Table 4](#table4-S1013702519500124){ref-type="table"}.

###### 

Baseline comparison of participants' quality of life between CTG and IRG.

![](hkpj-39-133-t004)

         CTG                 IRG                                
  ------ ------------------- ------------------ ------- ------- -------
  PF     54.57 $\pm$ 4.76    52.70 $\pm$ 4.88   2.160   0.036   0.147
  RLPH   52.38 $\pm$ 5.62    52.42 $\pm$ 7.35   2.625   0.016   6.808
  RLEP   67.09 $\pm$ 10.11   66.76 $\pm$ 5.57   0.463   0.080   0.499
  E/F    60.98 $\pm$ 7.64    62.64 $\pm$ 6.70   1.510   0.508   0.414
  EWB    65.67 $\pm$ 10.93   65.55 $\pm$ 6.52   0.463   0.025   0.223
  SF     57.65 $\pm$ 8.57    57.95 $\pm$ 5.71   1.646   0.023   0.205
  Pain   51.54 $\pm$ 7.67    50.92 $\pm$ 5.49   1.369   0.023   0.247
  GH     50.82 $\pm$ 6.94    51.57 $\pm$ 4.17   0.652   0.011   0.423
  PCS    52.37 $\pm$ 1.66    51.62 $\pm$ 2.56   4.210   0.054   0.540
  MCS    63.10 $\pm$ 2.42    63.29 $\pm$ 1.62   1.095   0.019   0.300

*Notes*: PCS: Physical component summary; MCS: mental component summary; PF: physical function; RLPH: role of limitation due to physical health; RLEP: role of limitation due to emotional problems; E/F: energy/fatigue; EWB: emotional well-being; SF: social functioning; GH: general health; M: mean; SD: standard deviation; and "\*" denotes the significance level, $p < 0.05$. "\*" indicates the statistical significance.

There was a statistically significant difference in quality of life between the two groups after 12 weeks of intervention: $F = 2.96$; $p = 0.005$; Wilk's $\text{lambda} = 0.623$; and partial eta-$\text{squared} = 0.37$. When the results for the dependent variables were considered separately, the only difference to reach statistical significance, using a Bonferroni-adjusted alpha level of 0.005, was general health (GH): $F = 14.64$, $p = 0.000$, and partial eta-$\text{squared} = 0.20$. An inspection of mean scores indicated combination therapy group reported higher levels of quality of life as shown in [Table 5](#table5-S1013702519500124){ref-type="table"}.

###### 

Post-treatment changes in QoL between the two groups (CTG and IRG).

![](hkpj-39-133-t005)

         CTG                 IRG                                
  ------ ------------------- ------------------- ------ ------- ----------
  PF     80.07 $\pm$ 07      75.52 $\pm$ 52      0.56   0.010   0.456
  RLPH   79.82 $\pm$ 7.87    74.05 $\pm$ 8.13    1.08   0.018   0.302
  RLEP   83.70 $\pm$ 12.66   78.60 $\pm$ 5.99    0.01   0.000   0.920
  E/F    65.14 $\pm$ 16.37   63.93 $\pm$ 9.05    0.05   0.001   0.001
  WB     78.37 $\pm$ 11.68   71.63 $\pm$ 11.46   0.03   0.001   0.850
  SF     75.24 $\pm$ 10.40   68.18 $\pm$ 10.25   1.02   0.017   0.316
  Pain   72.42 $\pm$ 8.88    67.33 $\pm$ 6.49    3.97   0.064   0.051
  GH     80.13 $\pm$ 11.69   52.70 $\pm$ 11.69   14.6   0.202   0.000^∗^
  PCS    78.27 $\pm$ 4.93    65.49 $\pm$ 3.49    7.84   0.119   0.007
  MCS    72.90 $\pm$ 14.08   68.96 $\pm$ 5.60    1.64   0.028   0.205

*Notes*: PCS: Physical component summary; MCS: mental component summary; PF: physical function; RLPH: role of limitation due to physical health; RLEP: role of limitation due to emotional problems; E/F: energy/fatigue; EWB: emotional well-being; SF: social functioning; GH: general health; M: mean; SD: standard deviation; "\*" denotes the significance level, $p < 0.005$.

Discussion {#section6-S1013702519500124}
==========

This was a randomized controlled trial, aimed at evaluating the efficacy of CTG when compared with ILG in terms of pain severity, functional activities, and HRQoL, in patients with knee osteoarthritis. The limitation of this study is that the long-term effects of combination therapy and infrared radiation cannot be obtained because the study only assesses the 12-week effects, therefore the results of this study should be interpreted with caution. The general applicability is limited as it can only be applied to the population of patients with knee osteoarthritis. Other limitation of the study includes the inability to blind the research assistant who delivered the intervention because in standard RCT both the participants and those who delivered the interventions are blinded but in physiotherapy it may sound so difficult. Self-reported outcomes such as VAS, WOMAC, and SF-36 scales are also a limitation as they may be influenced by placebo effects and outcome expectation. Moreover, some participants might have been taking other analgesics which might be a limitation to the intervention; this aspect is beyond the control of the researchers.

According to the study findings, patients with knee OA treated with CTG had better improvement in pain, physical function, and particularly the GH component of HRQoL compared with patients in the IRG, over a period of 12 weeks. This study clearly indicated that combination therapy is an electrotherapeutic modality that reduces pain and improves functional activities and HRQoL of elderly people with knee osteoarthritis.

In patients with OA, pain is the primary, most important, and frequent clinical symptom that leads to limited functional activities and poor quality of life.^[@bibr33-S1013702519500124],[@bibr34-S1013702519500124]^ The primary goal of OA management is to alleviate the pain as well as improve functional activities and the quality of life of the individuals.^[@bibr35-S1013702519500124]^

In the current study, significant pain improvement reported by the CTG might be attributed to the combined effects of the electro-analgesia of IFC^[@bibr11-S1013702519500124]^ therapy and thermal analgesic effects of continuous US therapy.^[@bibr36-S1013702519500124]^ Several studies have shown that CT is an effective modality in the management of musculoskeletal disorders.^[@bibr37-S1013702519500124],[@bibr38-S1013702519500124]^

Our findings were also supported by a study conducted by Švarcova *et al.*,^[@bibr39-S1013702519500124]^ who studied the combined effects of therapeutic ultrasound, galvanic current, and shortwave diathermy in patients with knee osteoarthritis. They reported significant improvement in pain level.

In spite of the fact that the mechanisms by which CT relieves pain are not properly understood, studies have shown that IFC therapy achieves its electro-analgesic effects through the activation of large diameter nerve fibres to inhibit the nociceptive impulses from the small-diameter fibres at the posterior horn of the spinal cord to modulate pain.^[@bibr11-S1013702519500124],[@bibr40-S1013702519500124]^ OA pain is believed to be originating from both nociceptive and neuropathic pains as well as from unusual excitability in the nociceptive pathways of both peripheral nervous system and central nervous system (CNS).^[@bibr41-S1013702519500124]^ The pain is proven to be associated with central sensitization as a result of continued nociceptive activities from the affected knee that leads to prolonged hyper-excitability of pain in the CNS.^[@bibr42-S1013702519500124],[@bibr43-S1013702519500124]^ IFC therapy may limit this prolonged abnormal hyper-excitation associated with pain observed in patients with knee OA. IFC therapy also achieves its electro-analgesic effects by blocking nociceptive impulses as explained by Melzack and Wall.^[@bibr44-S1013702519500124]^

Studies have shown that the application of continuous US therapy produces thermal effects.^[@bibr45-S1013702519500124],[@bibr46-S1013702519500124]^ Thermal therapies are physiologically known to increase tissue metabolism, collagen elasticity, capillary blood flow, and reduce muscle spasm.^[@bibr47-S1013702519500124],[@bibr48-S1013702519500124]^

Yeğin *et al.*^[@bibr36-S1013702519500124]^ reported that the US therapy is an effective treatment modality that reduces pain and improves physical function in the short term. In another study, Zeng *et al.*^[@bibr49-S1013702519500124]^ reported that the continuous US therapy could be used for effective pain relief in the management of knee osteoarthritis. Studies have shown that US therapy is an effective modality in reducing pain and improving functional activities and quality of life in the management of patients with knee OA.^[@bibr50-S1013702519500124],[@bibr51-S1013702519500124]^

Unlike our study and the above-reported findings, Welch *et al.*^[@bibr52-S1013702519500124]^ conducted a systematic review aimed at studying the effectiveness of US therapy for^[@bibr45-S1013702519500124]^ patients with knee OA. They reported US therapy to have no beneficial effects when compared with placebo and shortwave diathermy on pain and function in the management of patients with osteoarthritis. In addition, some controlled clinical studies have reported that US therapy had no benefits in improving pain and functional activities in the management of patients with knee osteoarthritis.^[@bibr45-S1013702519500124],[@bibr53-S1013702519500124]^

There is no literature that reports CT is unsafe. In all the available clinical studies on the use of CT on musculoskeletal disorders, no single study reported the side effects, either in CTG or in ILG.^[@bibr37-S1013702519500124],[@bibr38-S1013702519500124],[@bibr54-S1013702519500124]^ Likewise, in this current study no side effects had occurred during or after the CT treatment. Thus, the use of combination therapy was not associated with any negative or adverse effects in the management of knee OA.

The present study shows good improvement in pain relief, functional activities, and quality of life, but specifically the GH component of SF-36 quality of life showed improvement in patients treated with US and IFC therapies concurrently. The findings of this study add to the clinical evidence with regard to the use of CT in patients with knee OA.

Conclusion {#section7-S1013702519500124}
==========

Combination therapy was found to be an effective electrotherapeutic modality that can be used to relieve pain as well as improve functional activities and HRQoL in patients with knee osteoarthritis.
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